^
BIOMARKER:

PD-L1 expression

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
PD-L1 expression
Melanoma
pembrolizumab
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
PD-L1 expression
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD1 inhibitor
Sensitive
:
C3
Cancers (Basel) - 3 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 inhibitor
Sensitive
:
C3
Cancers (Basel) - 3 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
atezolizumab
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
durvalumab
Sensitive
:
A1
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Renal Cell Carcinoma
avelumab + axitinib
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
nivolumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Cervical Cancer
pembrolizumab + bevacizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
cemiplimab
Sensitive
:
A1
PD-L1 expression
Oral Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Oropharyngeal Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
ADX-2191
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
cetuximab
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
5-fluorouracil
Sensitive
:
A2
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Bladder Cancer
atezolizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
A2
PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Esophageal Adenocarcinoma
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Renal Cell Carcinoma
nivolumab
Sensitive
:
A2
PD-L1 expression
Head and Neck Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
nivolumab + ipilimumab
Sensitive
:
A2